EKF buys 360 Genomics for a "sensible" £1.6m to move into molecular Dx
This article was originally published in Clinica
UK firm EKF Diagnostics has made its first foray into the fast-growing molecular diagnostics sector, buying mutation detection specialist 360 Genomics and establishing a new subsidiary, EKF Molecular Diagnostics. The deal adds to EKF's current offering in point-of-care diagnostics, which is focused on diabetes and emerging markets.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.